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Background: MicroRNAs are a class of endogenous single strand non-coding RNAs that are involved in many
important physiological and pathological processes. The purpose of this study was to examine the expression levels
of miR-497 in human breast cancer and its function in MDA-MB-231 breast cancer cells.
Methods: Quantitative polymerase chain reaction was used to measure the expression levels of miR-497 in 40
breast cancer specimens and adjacent normal breast tissues. MTT assays, colony formation assays, wound healing
assays, transwell assays and cell cycle assays were used to explore the potential function of miR-497 in MDA-MB-231
breast cancer cells. Dual-luciferase reporter assays were performed to analyze the regulation of putative target of
miR-497, and western blot assays were used to validate the dual-luciferase results.
Results: The expression of miR-497 in breast cancer specimens was lower than adjacent normal tissues (P < 0.05).
Overexpression of miR-497 inhibited cellular growth, suppressed cellular migration and invasion, and caused a G1
arrest. Dual-luciferase reporter assays showed that miR-497 binds the 3′-untranslated region (3′-UTR) of cyclin E1,
suggesting that cyclin E1 is a direct target of miR-497. Western blot assays confirmed that overexpression of miR-497
reduced cyclin E1 protein levels.
Conclusions: MiR-497 may act as a tumor suppressor gene in breast cancer. Inhibited cellular growth, suppressed
cellular migration and invasion, and G1 cell cycle arrest were observed upon overexpression of miR-497 in cells,
possibly by targeting cyclin E1. These results indicate miR-497 could be considered a therapeutic target for the
development of treatment for breast cancer.
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MicroRNAs (miRNAs) are approximately 22-nucleotide
small RNAs that bind to the 3′-UTR of target mRNAs,
causing gene silencing via translational repression or target
degradation [1,2]. miRNAs are involved in many important
physiological and pathological processes, such as cell pro-
liferation, development, differentiation, virus infection and
tumorigenesis, and are widely dysregulated in various can-
cers [1,3-5]. Hundreds of miRNAs have been discovered in
mammals; however, the function of most miRNAs remains
largely unknown. Previous studies showed that miRNA-
497 (miR-497) was downregulated in several kinds of tu-
mors, including human melanoma [6], gastric cancer [7]
and adrenocortical carcinoma [8]. Similar results were also* Correspondence: fangzhuren301@163.com
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reproduction in any medium, provided the orobserved in breast cancer, in which the expression level of
miR-497 was significantly lower in breast cancer patients
and miR-497 levels inversely correlated with malignancy of
breast cancer [9-11]. A recent study by Shen et al.
suggested that miR-497 might induce apoptosis in MCF-7
breast cancer cells by targeting Bcl-w [9]. However,
whether miR-497 regulates other target genes to control
breast cancer cell growth and invasion is still unknown.
Cyclins are a family of proteins that control cell cycle
progression by activating cyclin-dependent kinases (CDKs)
and regulate the G1/S transition, DNA replication and mi-
tosis. Cyclin E1 binds and activates CDK2 to promote the
transition from G1 to S phase [12]. Previous studies
showed that cyclin E1 overexpression was critical in the
growth and survival of ovarian cancer cells and was signifi-
cantly associated with poor prognosis [13]. Similarly, breast
cancer patients with higher levels of cyclin E1 also showed. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 MiR-497 expression inhibits MDA-MB-231
proliferation. MTT cell proliferation assays were performed with
miR-497 and NC expressing cells. The proliferation of MDA-MB-231
cells transfected with miR-497 was inhibited in a dose- and time-
dependent manner compared with the NC group. The graph
represents OD Values ± SEM, *P < 0.05.
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[14-16].
In this study, we first demonstrated that the expression of
miR-497 was significantly lower in breast cancer specimens
compared with adjacent normal tissues. Overexpression of
miR-497 inhibited cellular growth, suppressed cellular
migration and invasion, and caused a G1 cell cycle arrest,
likely by targeting cyclin E1. These results indicate that
miR-497 may function as a tumor suppressor, and could be
a therapeutic target for the development of future
treatments for breast cancer.
Results
Expression of miR-497 was lower in breast cancer
specimens than adjacent normal tissues
The expression levels of miR-497 were measured by quanti-
tative polymerase chain reaction (qPCR) in forty breast can-
cer specimens and adjacent normal tissues. The results
showed that the expression of miR-497 was lower in breast
cancer specimens than adjacent normal tissues (Figure 1).
Overexpression of miR-497 in MDA-MB-231 cells inhibited
cell proliferation
Next we examined the effects of miR-497 expression on
cell proliferation by transfecting MDA-MB-231 cells with
miR-497 or negative control (NC) mimics and performing
MTT assays. Cells transfected with 50 nM and 100 nM
miR-497 mimics groups showed significantly lower optical
density (OD) values at 490 nm than the NC group from
day 2 until day 5, in a time- and dose-dependent manner
(Figure 2). Colony formation assays showed much less col-
ony formation in the group transfected with 100 nM miR-
497 compared with the NC group (Figure 3A, B). Together
these results demonstrated that transient overexpression of
miR-497 suppressed the colony formation ability of MDA-
MB-231 cells, and indicate that overexpression of miR-497
suppressed cellular proliferation.Figure 1 MiR-497 levels are significantly decreased in breast
cancer specimens. The graph represents the 2-ΔΔCt values ± SEM,
*P < 0.05.Overexpression of miR-497 in MDA-MB-231 cells inhibited
cell migration and invasion
To study how overexpression of miR-497 affects cellular
migration and invasion, we performed wound healing as-
says and transwell assays with MDA-MB-231 cells
transfected with miR-497 mimics (100 nM) or NC
mimics. The wound healing assay results showed that the
migration ability of the miR-497 mimic groups was lower
than the NC group. As shown in Figure 4, the cell-free
area of the miR-497 group was significantly wider than
the NC group at 24 h after drawing the “scratch” line on
the monolayer cells. While the NC group filled in the gap
at 48 h, the monolayer of miR-497-transfected cells still
showed a clear gap in the scratched region. These results
showed that overexpression of miR-497 in MDA-MB-231
cells inhibited cellular migration. In transwell invasion
assays, the number of invaded cells stained with Crystal
Violet was significantly less in the miR-497 (100 nM)
group (Figure 5A). Invasion rates of both groups were
determined by counting the number of cells that invaded
through matrigel and confirmed the results observed by
inverted microscope (Figure 5B). Together these results
indicated that overexpression of miR-497 can suppress
cellular migration and invasion ability.
Cell cycle was affected following overexpression of miR-
497 in MDA-MB-231 cells
The cell cycle distributions of the miR-497 (100 nM)
group and NC group were analyzed by flow cytometry.
As shown in Figure 6, the percentage of miR- 497-
transfected cells remaining in G1 phase was significantly
higher than the NC group (52.76 ± 0.09% vs. 45.04 ±
0.19%, respectively, P < 0.05), with approximately 7.72%
Figure 3 Overexpression of miR-497 inhibited colony formation ability of MDA-MB-231 cells. (A) Colony formation assays showed Crystal
Violet staining of the miR-497-transfected group and NC-transfected group. (B) Graph indicates colony numbers of each experimental transfected
group (60 ± 2 miR-497 group vs. 145 ± 2 NC group, *P < 0.05).
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with the NC group. These results indicated that the
overexpression of miR-497 could impact cell cycle
progression in MDA-MB-231 cells.
MiR-497 targets cyclin E1 and regulates its expression in
MDA-MB-231 cells
We searched for potential targets of miR-497 using several
online databases, including targetscan, miRanda, miRBaseFigure 4 Overexpressing of miR-497 in MDA-MB-231 cells showed im
gap of the scratched region of the miR-497-expressing MDA-MB-231 cells.and miRGen, and all four databases indicated that the
cyclin E1 mRNA contained miR-497 binding sites. To
examine the possibility that miR-497 targets cyclin E1, we
used dual-luciferase reporter assays, in which the reporter
activity is evaluated by normalizing the Renilla luciferase
(RL) activity with firefly luciferase (FL) activity, the FL/RL
ratio indicates the relative activity levels. We constructed
a psiCHECK-2/cyclin E1 3′-UTR vector, which contains
the RL gene and the 3′-UTR region of cyclin E1. Cellspaired migration in wound healing assays. (A) Image showed the
(B) Image showed the region of the NC group cells.
Figure 5 MiR-497 overexpression affects invasion ability of MDA-MB-231 cells. (A) Crystal Violet-stained invaded cells from transwell
experiments. Images were obtained on an inverted microscope with × 200 magnification. (B) Invasion rates were determined by counting the
number of cells invading through matrigel, *P < 0.05.
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with psiCHECK-2/cyclin E1 3′-UTR, and luciferase
activity was analyzed. The FL/RL ratio in the miR-497
group was approximately 1.5-fold higher than the NC
group (P < 0.05) (Figure 7B). Results were consistent over
three independent experiments. These results show that
miR-497 could directly interact with the cyclin E1 3′-UTRFigure 6 Overexpression of miR-497 in MDA-MB-231 cells caused G1
NC mimics were analyzed by flow cytometry. The respective proportion of
are indicated.in the psiCHECK-2 reporter plasmid, leading to the
degradation of RL mRNA.
Furthermore, western blot analysis (Figure 7C) showed
that cyclin E1 protein levels were lower in the miR-497
-overexpressing group compared with the NC group.
Taken together, these results indicate that miR-497 could
directly bind to the cyclin E1 3′-UTR region to regulatephase accumulation. MDA-MB-231 cells transfected with miR-497 or
G1 phase, S phase and G2 phase cells of miR-497 and NC groups
Figure 7 miR-497 targeted cyclin E1. (A) The miR-497 binding site in cyclin E1 3′-UTR, located 247–254 bp upstream of the cyclin E1 3′-UTR.
(B) The relative luciferase of activity in miR-497 group and NC group (*P < 0.05). (C) Western blot analysis of cyclin E1 protein levels in miR-497
-overexpressing and NC cells.
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binding site of miR-497 to cyclin E1 3′-UTR is located
247–254 bp upstream of the cyclin E1 3′-UTR.
Discussion
The study on the roles of miRNA in the development
of tumors has become a subject of intense investiga-
tion. It is estimated that approximately 30% of human
genes are miRNA targets [17]. One miRNA may have
multiple different mRNA targets, and at the same
time, one mRNA might be targeted by multiple
miRNAs. If the miRNA is perfectly complementary to
its target, it can specifically cleave the target mRNA.
However, if it is not perfectly complementary to its
target, the miRNA will inhibit mRNA translation.
Thus, the nature of the interactions between miRNAs
and their target genes forms a complicated regulatory
network [18,19]. Most miRNAs involved in the regula-
tion of tumor growth function through the two
pathways discussed above.
In this study, we examined the expression levels of
miR-497 in breast cancer specimens and adjacent nor-
mal tissues. We found that the expression of miR-497
was significantly lower in breast cancer specimens,
which suggested that the expression of miR-497 was as-
sociated with the development of breast cancer. Thus,
we hypothesized that miR-497 may function as a tumor
suppressor. Shen et al. reported that upregulation of
miR-497 expression in MCF-7 breast cancer cells causes
cellular growth inhibition, apoptotic enhancement and
G0/G1 phase arrest [9], in our study, we transfected
miR-497 mimics into MDA-MB-231 cells to induce its
overexpression. Exogenous overexpression of miR-497
significantly inhibited the cell growth as indicated by
MTT assays and colony formation assays. Moreover, cellmigration and invasion abilities were also significantly
reduced by overexpression of miR-497 in MDA-MB-231
cells, as shown by wound healing assays and transwell
assays. Furthermore, analysis of miR-497 mimic cells by
flow cytometry showed that miR-497 induced G1 arrest
compared with NC cells.
Our results have shown that overexpression of miR-497
in breast cells greatly influences cell proliferation, migra-
tion, invasion and cell cycle progression. We searched for
potential targets of miR-497 using several online data-
bases, including targetscan, miRanda, miRBase and
miRGen, and all four databases indicated that the cyclin
E1 mRNA contained miR-497 binding sites. The inter-
action between miR-497 and cyclin E1 mRNA has not
been previously reported. To test whether cyclin E1 is a
real target of miR-497, we constructed the psiCHECK-2/
cyclinE1 3′-UTR plasmid, which contains the 3′-UTR of
cyclin E1. Through dual-luciferase assays, we confirmed
the cyclin E1 3′-UTR as a direct target of miR-497 in
MDA-MB-231 cells. Additionally, we found that the
protein levels of cyclin E1 were significantly lower in
miR-497-overexpressing cells than those in NC cells.
Together, these findings support the prediction that cyclin
E1 is a downstream target of miR-497.
In summary, our findings suggest that miR-497 can
specifically regulate cell growth and invasion by targeting
cyclin E1 in MDA-MB-231 cells. Its overexpression can
inhibit cellular migratory ability and disrupt cell cycle
progression. Thus, these results indicate that miR-497
may acts as a tumor suppressor in breast cancer.
Moreover, the dual-luciferase and western blot assays
identify cyclin E1 as a downstream target of miR-497. The
artificial upregulation of miR-497 using cyclin E1 as a
therapeutic agent could offer a promising new direction
for future breast cancer treatment.
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Specimens
Forty paired breast cancer specimens and adjacent nor-
mal breast tissues were collected from the Department
of General Surgery of the Shanghai Tenth People’s
Hospital. The samples were immediately snap-frozen in
liquid nitrogen. All samples were confirmed as invasive,
ductal breast cancer by trained pathologists. No patients
received chemotherapy or radiotherapy prior to surgery.
The collection of the patient specimens were approved
by Institutional Ethics Committees of Tongji University,
the approval number: SHSY - IEC - pap3.0/13-3.Cell culture and transfection
Human MDA-MB-231 breast cancer cells and human
embryonic kidney 293T cells were obtained from the
Chinese Science Institute. The cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM; Gibco,
USA) supplemented with 10% fetal bovine serum (FBS;
Gibco), penicillin (100 units/ml) and streptomycin (100
μg/ml) (Enpromise, Hangzhou, China). Cells were incu-
bated at 37°C in a humidified chamber supplemented
with 5% CO2. Cells at approximately 90% confluence
were split at a 1:2 ratio every 3 days.
Cells (2 × 105) were added into each well of a 6-well plate
and cultured with DMEM medium without either serum or
antibiotics. When MDA-MB-231 cell density reached
30–40%, cells were transfected using lipofectamine transfec-
tion reagents (Invitrogen, USA), according to the manufac-
turer’s instructions. MiR-497 and NC mimics were purchased
from Gene Pharma (Shanghai, China), and sequences are as
follows: miR-497, 5′-CAGCAGCACACUGUGGUUUGU-
3′, and NC, 5′-UUGUACUACACAAAAGUACUG-3′. After
5–6 h of incubation, DMEM medium was replaced by
DMEM with 10% FBS.MicroRNA isolation and quantitative polymerase chain
reaction (qPCR)
miRNAs of forty paired breast cancer specimens and adja-
cent normal breast tissues were extracted using the
miRcute microRNA isolation kit (Tiangen, Beijing, China),
according to the manufacturer’s instructions. Expression
levels of miR-497 were analyzed by using one-step qRT-
PCR (EzOmics SYBR qPCR kit); the miR-497 stem-loop
primer, U6 primer and EzOmics SYBR qPCR kit were all
purchased from Biomics Biotechnology Inc (Jiangsu,
China). Real-time PCR was performed on a 7900HT fast
real time-PCR instrument (Applied Biosystems, Singapore)
using the following primers: miR-497:
5′-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGC
ACTGGATACGACACAAA-3′ (stem-loop primer), 5′-CG
CCAGCAGCACACTGTGG-3′ (sense) and 5′-GTGCAG
GGTCCGAGGT-3′ (antisense); U6:5′-GTCCTATCCAGTGCAGGGTCCGAGGTGCACTG
GATACGACAAAATATGGAAC-3′ (stem-loop primer),
5′-TGCGGGTGCTCGCTTCGCAGC-3′ (sense) and 5′-C
CAGTGCAGGGTCCGAGGT-3′ (antisense). RNA (100 ng)
was added in a 25 μl reaction mixture containing 12.5 μl
2× Master mix, 0.5 μl 50× SYBR Green, 0.5 μl reverse
transcription primer (10 μM), and 0.5 μl sense and 0.5 μl
antisense primers (10 μM) for miR-497. One step PCR pa-
rameters for miRNA quantification were as follows: 37°C
for 60 min for reverse transcription, 10 min at 95°C,
followed by 40 cycles of 20 sec at 95°C, 30 sec at 62°C and
30 sec at 72°C. Ct values were collected at the end of the
PCR. Each sample was tested in triplicate, and the relative
quantification equation was used to calculate the relative
expression.
Cell proliferation assay (MTT assay)
Cells (2 × 103) were plated in 96-well plates (BD
Biosciences, USA) and incubated at 37°C until the cells
reached 30–40% confluence, followed by transfection with
50 nM or 100 nM miR-497 or NC mimics. Cell prolifera-
tion was assessed at 24, 48, 72, 96 and 120 h as follows: 20
μl (5 mg/ml) MTT solution (Sigma, USA) was added in
each well, and after 4 h of incubation at 37°C, the super-
natant was discarded and 150 μl of dimethyl sulfoxide
(DMSO) were added. After 10 min of low speed shaking
(100 rpm) and incubation, the OD at 490 nm was read by
a microplate spectrophotometer. Each sample was tested
with six replicates. All experiments were performed in
biological triplicate.
Colony formation assay
After transfection with 100 nM miR-497 or NC mimics,
400 cells were plated in a 6-well plate in complete
medium, and the plate was shaken to disperse the cells
equally. After incubation at 37°C with 5% CO2 for 7–10
days, when the colonies were visible by eye, the culture
was terminated by removing the medium and washing
cells twice with phosphate-buffered saline (PBS). The
colonies were fixed with 95% ethanol for 10 min, dried
and stained with 0.1% Crystal Violet solution for 10 min,
and the plate was washed three times with water. Images
were taken of the stained plates, and the numbers of
colonies containing more than 50 cells were counted.
Each treatment was performed in triplicate.
Cell migration and invasion assay
Cell migration was evaluated by the wound healing
assay, also known as the “scratch” assay. MDA-MB-231
cells were transfected with miR-497 mimics (100 nM) or
NC mimics, and when cells reached 90% confluence, a
scratch was made through each well using a sterile
pipette tip. Cells were monitored under the microscope
(magnification, ×50) for 0, 12, 24 and 48 h after
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position before and after incubation to document the
repair process. The experiments were repeated three
times.
Transwell invasion assays were performed to evaluate
invasion ability as follows: 1 ml 10% FBS DMEM was
added into a 24-well plate, and a transwell filter insert was
placed into the well; the filter was filled with 5 × 104 cells
(miR-497-transfected or NC-transfected cells) in 200 μl
DMEM with 0.1% BSA, and the cells were cultured for 30
h at 37°C in 5% CO2. Invasion was observed under an
inverted microscope, and when the cells crossed into the
basal well, the invasion was terminated. The matrigel was
scraped off, and numbers of cells remaining in the basal
well were analyzed. The filters were washed three times
with PBS, fixed with 4% paraformaldehyde, stained by
0.1% Crystal Violet solution, and washed three times with
water. Images of the stained cells were obtained. To quan-
tify the number of invading cells, Crystal Violet-stained
cells in 10 random visual fields were counted, and means
were obtained for statistical analysis.
Cell cycle analysis
MDA-MB-231 cells transfected with miR-497 (100 nM)
or NC mimics were harvested 36 h after transfection,
centrifuged at 1,200 rpm for 10 min and washed three
times with cold PBS. Ice-cold 70% ethanol was added
dropwise, and cells were fixed in 4°C overnight. After 30
min digestion by RNase (0.1 g/L), 250 μl propidium iodide
staining solution (0.05 g/l) was added to each sample.
Cells were incubated for 30 min at room temperature in
the dark and analyzed by a flow cytometer (FACSCanto™
II, BD Biosciences).
Dual-luciferase reporter assay
293T cells were seeded in 12-well plates (BD, USA) and
cultured until the cells reached 80–90% confluence. The
Cyclin E1 3′-UTR was cloned into the psiCHECK-2
vector, which contains the RL gene, and co-transfected
into cells together with miR-497 or NC mimics (100 nM)
using lipofectamine, according to the manufacturer’s
instructions. Thirty hours after transfection, luciferase
activity was measured using the Dual-Luciferase Reporter
assay kit (Promega, USA). Briefly, the cells were washed
twice with PBS, lysed with passive lysis buffer and incu-
bated at room temperature for 15 min. The supernatants
were collected and 20 μl were added into 96-well plates.
The FL reporter was measured immediately after adding
luciferase assay reagent II (LAR II). After quantifying the
firefly luminescence, 100 μl Stop&Glo® Reagent was
added to each well to initiate the RL reporter and Renilla
luminescence was then measured. The data were ana-
lyzed by normalizing RL with FL, and the ratio of FL/RL
was calculated to indicate the activity of the reporter.Western blot analysis
Cells were washed twice by cold PBS, and RIPA lysis buffer
was added (1% Triton X-100, 50 mmol/L Tris pH 7.4, 150
mmol/L NaCl, 20 mmol/L Iodoacetamide, 1 mmol/L
Phenylmethanesulfonyl fluoride and 1% aprotinin). Cells
were lysed on ice for 30 min, the cell lysate was collected
into microtubes, and samples were centrifuged for 15 min
at 12000 rpm at 4°C. Supernatants were collected and the
protein concentrations were measured using the BCA Pro-
tein Assay Kit (Beyotime, Jiangsu, China). Protein samples
(25 μg) were denatured with 5× sodium dodecyl sulfate
(SDS) loading buffer (100 mmol/L Tri-HCl pH 6.8, 4%
SDS, 0.2% bromophenol blue, 20% glycerin, 200 mmol/L
β-mercaptoethanol) at 95°C for 5 min. Protein samples
were separated on a 10% SDS polyacrylamide gel electro-
phoresis and transferred onto 0.45 μm nitrocellulose
membranes (Beyotime). Following 60 min of blocking with
5% fat-free milk, membranes were incubated with cyclin
E1 antibody (1:1000, Epitomics, USA) and β-actin antibody
(1:1000, Epitomics) overnight at 4°C. Blots were washed
and incubated for 1 h with the anti-rabbit secondary
antibody (1:1000, Epitomics). After three washes with
PBST, immunoreactive protein bands were detected with
an Odyssey Scanning system (Li-Cor, Lincoln, NE, USA).
Statistical analysis
Data are presented as the mean ± standard error of mean
from at least three independent experiments. The two-
tailed t-test was used to draw a comparison between
groups. The null hypothesis was rejected at the 0.05 level.
Abbreviations
miRNA: microRNA; NC: Negative control; qPCR: quantitative polymerase chain
reaction; nM: nmol/l; FBS: Fetal bovine serum; DMEM: Dulbecco’s modified
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